# OmniAb

### Deep Screening in Harmony with AI for Bispecific Antibody Discovery

Bob Chen, PhD *Sr. Director, Discovery Systems* May 15, 2024



## The OmniAb Technology Offering is Expanding

TECHNOLOGY OFFERING ADDRESSES THE MOST CRITICAL CHALLENGES OF ANTIBODY DISCOVERY


Create Diverse Repertoires of High-Quality AntibodiesScreen Millions of Cells to Find Potential Therapeutic CandidatesComputational Antigen Design &Computational Antigen Design &	Further Characterize, Select and Optimize the Right Antibody
Computational vPloration <sup>®</sup>	
Dronriotary Doggonte	stom Bioinformatics
Frophetury Reagents         FormiRat OmniChicken         Robust Antibodies for Any Target         Formiflic OmniClic         Bispecific Antibody Generation	3
Signation     Signation	• Proprietary Ion Channel Assays
OmnidAb OmniTaur • STR: H	Fc-Silencing hology* STR

OmniDeep<sup>\*</sup> Suite of in silico tools for discovery and optimization that are woven throughout our various technologies and capabilities. Includes structural modeling, large multi-species antibody databases, molecular dynamics simulations, AI, and machine and deep learning sequence models, and more

\*OmniAb entered into an agreement with mAbsolve Ltd. for STR, mAbsolve's Fc-silencing platform technology, which provides OmniAb with exclusive, sublicensable right to incorporate the STR technology with antibodies that have been generated using OmniAb's antibody discovery platform.

## **Custom Antibody Repertoires for Every Target**

**Biological Intelligence**<sup>™</sup>**:** Interplay between rational genetic design and powerful *in vivo* processes



Biological Intelligence can create a vast and diverse antibody repertoire within and across animals



## **OmniAb Antibody Repertoires**

### BROAD PLATFORM AVAILABLE TO ADDRESS DIVERSE PARTNER OBJECTIVES

Host	V genes	Structural and immunological features	Benefits for therapeutics discovery and development
-SomniMouse	<ul><li>Full human V gene diversity</li><li>Choice of light chain isotype</li></ul>	<ul> <li>Diverse V gene usage and mixed genetic backgrounds</li> </ul>	Widely accessible and flexible workflows
<b>S</b> omniRat <sup>®</sup>	<ul><li>Full human V gene diversity</li><li>Choice of light chain isotype</li></ul>	<ul> <li>Diverse V gene usage and mixed genetic backgrounds</li> <li>Distinctive target recognition</li> </ul>	<ul> <li>Industry standard</li> <li>Widely accessible and flexible workflows</li> <li>Extensive track record</li> </ul>
OmniĈhicken	<ul><li>Single framework</li><li>VH3/VK3 or VH3/VL1</li></ul>	Evolutionarily divergent host system for robust immune responses	<ul> <li>Diverse and new epitope coverage</li> <li>High homology targets</li> <li>Excellent physical properties</li> </ul>
	Full human VH gene diversity with non-diversifying VK3	<ul> <li>Fixed light chain for bispecific applications</li> </ul>	<ul> <li>Bispecific applications leveraging standard IgG format</li> </ul>
OmniĈlic	<ul><li>Single framework</li><li>VH3/non-diversifying VK3</li></ul>	<ul> <li>Fixed light chain for bispecific applications</li> </ul>	<ul> <li>Diverse epitope coverage</li> <li>Excellent physical properties</li> <li>Ease of manufacturing</li> </ul>
OmniâAb	• Single camelized human VH framework with truncated LC	• Domain antibody of the "VHH" type	<ul> <li>Diverse and new epitope coverage from human single-domain format, 12-15kD</li> <li>Building blocks for multispecific molecules</li> </ul>
OmniTaur"	<ul><li>Single framework</li><li>VH4/VL1</li></ul>	<ul> <li>Ultralong CDR-H3's for enormous structural diversity</li> </ul>	<ul> <li>Access cryptic epitopes</li> <li>Unique modalities (picobodies<sup>™</sup>)</li> <li>Building blocks for multispecific molecules</li> </ul>

OmniAb

### **OmniAb's Common Light Chain Platforms**





Fixed human VK3-15 light chain expressed with diversifying heavy chain from *any* human germline (44 VHs)






Fixed human VK3-15 light chain combined with diversifying heavy chain on single scaffold (VH3-23) for superior developability


\*Classical IgG format may de-risk downstream development of bispecifics Gera, Expert Opin Biol Ther. 2022

OmniFlic<sup>®</sup> & OmniClic<sup>®</sup> enable IgG-like asymmetric formats



Omni<mark>Ab</mark>

## **Deep Screening Platforms**



Our powerful single B-cell screening technologies, **xPloration® and GEM assay**, **bypass bottlenecks of hybridoma workflows** 


Al-driven multi-parameter screening of **tens of millions** of cells in **hours instead of weeks** 

Technologies enable **screening against difficult targets**: GPCRs, ion channels and surface antigens




### xPloration<sup>®</sup>: Al-Driven Deep Functional Screening


### 1 | Loading



Unique through-hole format


### 2 | Assay + Machine Vision





Machine vision hit detection


### 3 | Recovery & Single-Cell NGS




Precise laser-based recovery Single-cell barcoding or pooled




### Multi-Parameter Screening: Multiplex Phenotypic Data




### Selective binding of target cell






OmniAb


### **Rapid Laser Recovery of Hits**





### 1x speed video of laser recovery








# OmniAb

## NKp46 Case Study

Discovering NK cell engager arm for bispecific antibody




### **Project Background**



### Discover anti-NKp46 antibodies using OmniFlic and OmniClic for bispecific antibody



## **OmniDeep® Empowers Large-Scale Antibody Discovery**





### **OmniFlic<sup>®</sup> Screening Summary**




	Screen Type	# Cells Screened	# Hits	
1	Antigen on beads	5 M	1429	
I	Cells	7.7 M	345	
2	Antigen on beads	3.7 M	751	
2	Cells	3.7 M	158	
2	Antigen on beads	3.7 M	308	
3	Cells	3.7 M	33	
	Total	27.5 M	3024	

Processed with pooled NGS sequencing for 1375 unique sequences

Synergy between OmniFlic, xPloration<sup>®</sup> and NGS enables large-scale repertoire mining




### **OmniFlic<sup>®</sup> Repertoire Space**






### **Bioinformatics-Aided Antibody Selection**



In silico tools guide data-driven antibody selection process

OmniAb

### **Discovery of High Affinity NKp46 Binders**



xPloration<sup>®</sup> OmniFlic campaigns are available to partners



## **OmniClic<sup>®</sup> Screening Summary**



Bird	Screen Type	# Cells Screened	# Hits	
1	Antigen on beads	1.4 M	1200	
1	Cells	3.2 M	203	
2	Antigen on beads	1.4 M	1199	
2	Cells	3.1 M	602	
2	Antigen on beads	2.6 M	1326	
3	Cells	1.3 M	699	
	Total	13 M	5229	

Processed with pooled NGS sequencing for **2130 unique sequences** 

Synergy between OmniClic, xPloration<sup>®</sup> and NGS enables large-scale repertoire mining



Omn	iClic® F	Repert	oire S	pace					
ID: 1 (n=2		ID: 3 (n=125)	ID: 4 (n=91)	ID: 5 (n=90)	ID: 6 (n=60)	ID: 7 (n=55)	ID: 8 (n=51)	ID: 9 (n=51)	ID: 10 (n=40)
					0			٩	
ID: 11 (n=	38) ID: 12 (n=36)	ID: 13 (n=32)	ID: 14 (n=31)	ID: 15 (n=27)	ID: 16 (n=26)	ID: 17 (n=25)	ID: 18 (n=24)	ID: 19 (n=23)	ID: 21 (n=22)
£3			0	0			• • • • •		
ID: 20 (n=	22) ID: 22 (n=21)	ID: 23 (n=18)	ID: 24 (n=16)	ID: 25 (n=16)	ID: 26 (n=14)	ID: 27 (n=14)	ID: 28 (n=14)	ID: 32 (n=12)	ID: 34 (n=12)
ID: 33 (n=	12) ID: 30 (n=12)	ID: 31 (n=12)	ID: 29 (n=12)	ID: 35 (n=11)	ID: 36 (n=11)	ID: 37 (n=11)	ID: 38 (n=11)	ID: 40 (n=9)	ID: 39 (n=9)
ID: 41 (n=	=8) ID: 42 (n=8)	ID: 43 (n=8)	ID: 44 (n=8)	ID: 49 (n=7)	ID: 52 (n=7)	ID: 51 (n=7)	ID: 50 (n=7)	ID: 48 (n=7)	ID: 47 (n=7)
	•	•••••	• • •	•	••••	••••	••••	• • •	•
									$\bigcirc$






### **Discovery of NKp46 Binders**



# Selected Clones	Binding (%)	<10 nM (%)			
178	49	6%			
<ul> <li>Expressed clones with common light chain</li> </ul>					
<ul> <li>88 confirmed binders</li> </ul>					

- 88 confirmed binders
  - Average affinity ~100 nM




Can we employ deep learning to increase yield and affinity?




## Integrating Biological Intelligence<sup>™</sup> with AI

IN SILICO TOOLS TO BETTER MINE DIVERSE IMMUNE REPERTOIRES



### **Encoding Sequence Space with Deep Learning**



- Input data: xPloration<sup>®</sup> sorted sequences, bulk NGS, and affinity data
- Organization is purely data-driven both by the provided sequence and given affinity data

22

JmniAh

## **Active Learning for Clone Selection**

### Active Learning


- Uncertainty estimates drive novel region exploration
- Most efficient learning of predictive models
- Statistically driven exploration of sequence space
- Iterations between deep learning and experiment
- Expected Improvement
  - Bayesian optimization acquisition function
    - Mathematical formulation guiding the selection of new samples
  - Function that has inputs of
    - Estimated mean (µ)
    - Estimated standard deviation (σ)
    - Current observed maximum (s<sub>max</sub>)



## Identifying Higher Affinity Antibody Sequences


SELECTION FROM UNLABELED POOL OF DATA

 Expected Improvement (EI) of the entire unlabeled data set can be calculated and sequences with highest values are selected





### **VAE Highlight New Clones to Characterize**




VAE Selected

Bead screen

Cell screen


### **OmniDeep® Successfully Selected High Affinity Clones**



Successfully found additional unique clones at 91% rate with ~10x improvement in mean affinity



### **OmniDeep**<sup>®</sup> Leverages Deep Learning




AI suggests additional high affinity and developable antibody sequences




## Integrating Biological Intelligence<sup>™</sup> with AI

IN SILICO TOOLS TO BETTER MINE DIVERSE IMMUNE REPERTOIRES




## **Mammalian Secretion Libraries and xPloration®**

EMPOWERING LARGE-SCALE HIGH-QUALITY EVALUATION OF SEQUENCES



- One library variant per cell: phenotype/genotype linkage
- Secretion rate comparable to native B cells




- Assay detects secretion of IgG and binding of target
- Enables sorting of binding sequences and non-binding sequences



## **Mammalian Library Sort**


### POSITIVE AND NEGATIVE DATA FOR ML MODELS



Successfully evaluated ~1500 selections and sorted for positive and negative binding sequences




### **xPloration<sup>®</sup> Sorting Enriches Binders/Non-binders**



## **Scoring Sequences for Selection and Model Training**


32

SCORE = POSITIVE COUNTS – NEGATIVE COUNTS



### **Next Active Learning Cycle Empowered by xPloration®**

**Round 2 Selection** 



Efficient guided evaluation of repertoire space for high affinity sequences



### **Deep Screening in Harmony with Al**

xPloration<sup>®</sup> enables large-scale data collection from Biological Intelligence for training OmniDeep<sup>™</sup> models

xPloration facilitates efficient evaluation of AI selections from OmniAb immune repertoires

Synergy between OmniFlic® and OmniClic®, xPloration, and OmniDeep enables new bispecific antibody discovery workflows for partners

## OmniDeep®

× Ploration®



# OmniAb



Advanced Antigen Design Strategies for Shaping Human Antibody Repertoires in OmniAb Animals June 12, 2024 | 9 AM PT | 12 PM ET

Devendra Srivastava, PhD Director, Protein Sciences OmniAb, Inc.



# OmniAb

## THANK YOU!

### Visit us at Booth #504

www.OmniAb.com



